高级检索
当前位置: 首页 > 详情页

Microenvironment characterization and multi-omics signatures related to prognosis and immunotherapy response of hepatocellular carcinoma

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

单位: [1]Huazhong Univ Sci & Technol,Hepat Surg Ctr,Tongji Hosp,Tongji Med Coll,1095 Jiefang Ave,Wuhan 430030,Hubei,Peoples R China [2]Hubei Prov Clin Med Res Ctr Hepat Surg, Wuhan 430030, Hubei, Peoples R China [3]Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Anesthe Siol, Wuhan 430022, Peoples R China [4]Huazhong Univ Sci & Technol,Tongji Hosp,Tongji Med Coll,Dept Gynecol & Obstet,Wuhan 430030,Peoples R China [5]Huazhong Univ Sci & Technol, Clin Med Coll 2, Tongji Med Coll, Wuhan, Peoples R China
出处:
ISSN:

关键词: Hepatocellular carcinoma Immune subtypes Multi-omics signatures Immunotherapy MMP9

摘要:
Background Immune cell infiltration in the tumor microenvironment (TME) affects tumor initiation, patients' prognosis and immunotherapy strategies. However, their roles and interactions with genomics and molecular processes in hepatocellular carcinoma (HCC) still have not been systematically evaluated. Methods We performed unsupervised clustering of total 1000 HCC samples including discovery and validation group from available public datasets. Immune heterogeneity of each subtype was explored by multi-dimension analysis. And a support vector machine (SVM) model based on multi-omics signatures was trained and tested. Finally, we performed immunohistochemistry to verify the immune role of signatures. Results We defined three immune subtypes in HCC, with diverse clinical, molecular, and genomic characteristics. Cluster1 had worse prognosis, better anti-tumor characteristics and highest immune scores, but also accompanied by immunosuppression and T cell dysfunction. Meanwhile, a better anti-PD1/CTLA4 immunotherapeutic response was predicted in cluster1. Cluster2 was enriched in TAM-M2 and stromal cells, indicating immunosuppression. Cluster3, with better prognosis, had lowest CD8 T cell but highest immune resting cells. Further, based on genomic signatures, we developed an SVM classifier to identify the patient's immunological status, which was divided into Type A and Type B, in which Type A had poorer prognosis, higher T cell dysfunction despite higher T cell infiltration, and had better immunotherapeutic response. At the same time, MMP9 may be a potential predictor of the immune characteristics and immunotherapeutic response in HCC. Conclusions Our work demonstrated 3 immune clusters with different features. More importantly, multi-omics signatures, such as MMP9 was identified based on three clusters to help us recognize patients with different prognosis and responses to immunotherapy in HCC. This study could further reveal the immune status of HCC and provide potential predictors for immune checkpoint treatment response.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2019]版:
最新[2025]版:
大类 | 2 区 医学
小类 | 2 区 血液学 2 区 肿瘤学
JCR分区:
出版当年[2018]版:
最新[2023]版:
Q1 HEMATOLOGY Q1 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2018版] 出版当年五年平均 出版前一年[2017版] 出版后一年[2019版]

第一作者:
第一作者单位: [1]Huazhong Univ Sci & Technol,Hepat Surg Ctr,Tongji Hosp,Tongji Med Coll,1095 Jiefang Ave,Wuhan 430030,Hubei,Peoples R China [2]Hubei Prov Clin Med Res Ctr Hepat Surg, Wuhan 430030, Hubei, Peoples R China [5]Huazhong Univ Sci & Technol, Clin Med Coll 2, Tongji Med Coll, Wuhan, Peoples R China
通讯作者:
通讯机构: [1]Huazhong Univ Sci & Technol,Hepat Surg Ctr,Tongji Hosp,Tongji Med Coll,1095 Jiefang Ave,Wuhan 430030,Hubei,Peoples R China [2]Hubei Prov Clin Med Res Ctr Hepat Surg, Wuhan 430030, Hubei, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:426 今日访问量:0 总访问量:410 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)